Dr. Barbara Weber Joins ITM Supervisory Board for Growth

Barbara Weber, M.D., Joins ITM Supervisory Board

Garching / Munich, Germany – ITM Isotope Technologies Munich SE (ITM), a front-runner in the radiopharmaceutical sector, recently announced the election of Barbara Weber, M.D., to its Supervisory Board, starting on May 01. This decision was made during an extraordinary general meeting of the company. With a distinguished career that includes founding Tango Therapeutics (NASDAQ: TNGX), Dr. Weber brings a wealth of experience in biotechnology and pharmaceuticals.

Expertise That Matters

Dr. Weber's impressive track record of over 25 years in various roles, including executive leadership and research, will provide a significant advantage to ITM as it works on its leading Phase 3 candidate, n.c.a. 177Lu-edotreotide (ITM-11). Her extensive knowledge, honed from her time at renowned organizations like Novartis (NYSE: NVS) and GlaxoSmithKline (NYSE: GSK), will be instrumental in propelling ITM's initiatives within the radiopharmaceutical sector.

Vision for Targeted Therapy

Upon her appointment, Dr. Weber expressed her excitement about the potential of targeted radiopharmaceutical therapy in precision oncology. She recognizes the capabilities of this innovative approach to significantly enhance treatment outcomes for cancer patients. "I am eager to collaborate with ITM's Supervisory Board and leadership team as we prepare for an NDA submission for ITM-11 and broaden our pipeline with various targeted radiopharmaceuticals," she stated.

Building on a Strong Foundation

Prior to this role, Dr. Weber served as Senior Vice President of Oncology Translational Medicine at Novartis and as Vice President at GlaxoSmithKline, where she played pivotal roles in obtaining FDA approvals for various oncology drugs. Her deep expertise as a physician-scientist will bring a fresh perspective to ITM, as she has been involved in numerous drug discovery projects aimed at improving cancer treatments.

ITM's Commitment to Innovation

ITM prides itself on its dedication to developing advanced radiopharmaceutical products that cater to patients with hard-to-treat tumors. The company is focused on enhancing the lives of cancer patients through cutting-edge research and innovation in medical radioisotope manufacturing. With Dr. Weber's experience and insight on board, ITM is well-positioned to enhance its existing initiatives.

About ITM Isotope Technologies Munich SE

ITM is committed to delivering a new wave of radiopharmaceutical treatments and diagnostics. The company is focused on addressing the needs of patients and healthcare providers by excelling in the development and global supply of innovative solutions. As part of its mission, ITM continues to progress its precision oncology pipeline, which features multiple Phase 3 studies combining its high-quality radioisotopes with advanced targeting molecules.

For more details, please contact:

Corporate Communications

Kathleen Noonan / Julia Westermeir
Phone: +49 89 329 8986 1500
Email: communications@itm-radiopharma.com

Investor Relations

Ben Orzelek
Phone: +49 89 329 8986 1009
Email: investors@itm-radiopharma.com

Frequently Asked Questions

Who is Dr. Barbara Weber?

Dr. Barbara Weber is the President, CEO, and founder of Tango Therapeutics, with over 25 years of experience in the biotech sector.

What is ITM's focus?

ITM focuses on developing radiopharmaceuticals and medical radioisotopes for treating hard-to-treat tumors and improving patient outcomes.

When will Dr. Weber begin her role at ITM?

Dr. Weber will formally assume her role on the Supervisory Board beginning May 01.

What notable companies has Dr. Weber worked at?

Dr. Weber has held key positions at Novartis and GlaxoSmithKline, among others.

What is ITM-11?

ITM-11 is ITM's lead candidate in Phase 3 trials, aimed at improving treatment outcomes in oncology.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.